【重大事项】 国泰航空(00293)购买十四架波音777-9型飞机 恒瑞医药(01276)：注射用瑞康曲妥珠单抗联合阿得贝利单抗注射液和化疗用于胃癌或胃食管结合部腺 癌适应症获得美国 FDA孤儿药资格认定 中国生物制药(01177) 自主研发的罗伐昔替尼片"TQ05105 (JAK/ROCK抑制剂)"被纳入突破性治疗药物程 序 复宏汉霖(02696)：HLX79注射液联合汉利康® 治疗活动期肾小球肾炎的2期临床研究于中国境内完成首 例患者给药 瑛泰医疗(01501)拟出资不超过1.1亿元参设怀格广泰基金 国泰航空(00293)发布中期业绩 股东应占溢利36.51亿港元 同比增长1.1% 中期息每股20港仙 统一企业中国(00220)发布中期业绩，股东应占溢利12.87亿元，同比增加33.24% 百济神州(06160)发布第二季度业绩 净利润9432万美元 同比扭亏为盈 新鸿基公司(00086)发盈喜 预计中期股东应占溢利同比增加至不低于8亿港元 维信金科(02003)发盈喜，预期中期综合净利润不少于2亿元 同比大幅增长 赤子城科技(09911)发盈喜 预计中期股东应占利润同比增长约108.9%至126.7% ...

1）业绩速递 百济神州(06160.HK)：上半年营收175.18亿元，同比上升46%；产品收入为173.6亿元，同比上升45.8%；净利润4.5亿元，同比扭亏为盈。 统一企业中国(00220.HK)：上半年收入约为170.87亿元，同比上升10.6%；净利润约12.87亿元，同比上升33.2%。 赤子城科技(09911.HK)：发布盈喜，预计中期收入约31.35亿-32.15亿元，同比增约38.0%-41.5%；净利润约为4.7亿-5.1亿元。同比增长约108.9%-126.7%。 智通财经8月6日讯（编辑 冯轶 汤赞淇）智通财经为您带来今日港股重要公告 维信金科(02003.HK)：发布盈喜，预计中期净利润超2亿元，同比大幅增长。 翼辰实业(01596.HK)：发布盈喜，预计中期净利润约4870万元，同比扭亏为盈。 华显光电(00334.HK)：发布盈喜，预计中期净利润超4880万元，同比增超600%。 迈富时(02556.HK)：发布盈喜，预计中期净利润约3180万-4100万元，同比扭亏为盈。 心玮医疗-B(06609.HK)：发布盈喜，预计中期净利润超4000万元，同比扭亏为盈。 中国核能科技(00 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海復宏漢霖生物技術股份有限公司 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02696 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 163,428,541 | RMB | | 1 RMB | | 163,428,541 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 163,428,541 | RMB | | 1 RMB | | 163,428,541 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請 ...

Core Viewpoint - The company has initiated the first patient dosing in a Phase II clinical study of HLX79 injection combined with Hanlikang for the treatment of active glomerulonephritis in mainland China [1][2]. Group 1: Clinical Study Overview - The study is a double-blind, randomized, controlled, multi-center Phase II trial aimed at evaluating the efficacy, safety, and tolerability of HLX79 combined with Hanlikang compared to a placebo in patients with active glomerulonephritis, including lupus nephritis (LN) and membranous nephropathy (MN) [2]. - The study consists of two phases: the first phase is a dose-escalation period where eligible participants will receive HLX79 (10 mg/kg, 20 mg/kg, or 30 mg/kg) combined with either Hanlikang or a Hanlikang placebo (375 mg/m²) weekly [2]. - The second phase is a preliminary efficacy exploration period, where eligible participants will receive HLX79 (high dose/low dose) combined with Hanlikang (375 mg/m²), HLX79 placebo combined with Hanlikang, or HLX79 placebo combined with Hanlikang placebo weekly, with the primary objective of evaluating clinical efficacy [2]. Group 2: Market Context - As of the date of the announcement, there are no similar combination therapies approved for marketing globally [3].

格隆汇8月6日丨复宏汉霖(02696.HK)发布公告，近日，一项HLX79注射液(人唾液酸酶融合蛋白) ("HLX79")联合汉利康®(利妥昔单抗注射液)("汉利康®")治疗活动期肾小球肾炎的2期临床研究于中国境 内(不包括中国港澳台地区)完成首例患者给药。 ...

Core Viewpoint - The company Fuhong Hanlin (02696) has announced the completion of the first patient dosing in a Phase II clinical trial for HLX79 injection combined with Hanlikang (Rituximab injection) for the treatment of active glomerulonephritis in China, excluding Hong Kong, Macau, and Taiwan [1] Group 1 - The study is a double-blind, randomized, controlled, multi-center Phase II clinical trial aimed at evaluating the efficacy, safety, and tolerability of HLX79 combined with Hanlikang compared to placebo in patients with active glomerulonephritis, specifically lupus nephritis (LN) and membranous nephropathy (MN) [2] - The trial consists of two phases: the first phase is a dose-escalation period where eligible participants will receive weekly doses of HLX79 (10 mg/kg, 20 mg/kg, or 30 mg/kg) combined with Hanlikang or Hanlikang placebo (375 mg/m²) [2] - The primary objective of the first phase is to assess the safety and tolerability of HLX79 combined with Hanlikang compared to placebo combined with Hanlikang in treating active glomerulonephritis [2] Group 2 - The second phase is an exploratory efficacy phase where eligible participants will receive weekly doses of HLX79 (high dose/low dose) combined with Hanlikang (375 mg/m²), HLX79 placebo combined with Hanlikang, or HLX79 placebo combined with Hanlikang placebo in a 2:2:1:1 ratio [2] - The primary objective of the second phase is to evaluate the clinical efficacy of HLX79 combined with Hanlikang, placebo combined with Hanlikang, and placebo treatment for active glomerulonephritis on top of standard treatment [2] - Secondary objectives include assessing other clinical efficacy, safety, tolerability, pharmacokinetic characteristics, and immunogenicity, while exploratory objectives aim to evaluate the dynamic changes of potential biomarkers [2] - As of the date of the announcement, there are no similar combination therapies approved for marketing globally [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Henlius Biotech, Inc. 上海復宏漢霖生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2696） 自願公告 HLX79注射液（人唾液酸酶融合蛋白） 聯合漢利康® （利妥昔單抗注射液） 治療活動期腎小球腎炎的 2期臨床研究於中國境內完成首例患者給藥 A. 緒言 本公告由上海復宏漢霖生物技術股份有限公司（「本公司」）自願作出，以告知 本公司股東及潛在投資者本公司最新業務更新。 本公司董事會（「董事會」）欣然宣布，近日，一項HLX79注射液（人唾液酸酶 融合蛋白）（「HLX79」）聯合漢利康® （利妥昔單抗注射液）（「漢利康®」）治療活 動期腎小球腎炎的2期臨床研究於中國境內（不包括中國港澳台地區，下同） 完成首例患者給藥。 B. 臨床試驗設計及目的 本研究為一項雙盲、隨機對照、多中心的2期臨床試驗，旨在評估HLX79 聯合漢利康®對比安慰劑在活 ...

Core Insights - Adidas reported a 7% year-on-year revenue growth for FY2025H1, reaching €12.105 billion, with a net profit increase of 121% to €798 million [4] - The brand's revenue growth was 14% on a currency-neutral basis, with all regional markets achieving double-digit growth [4] - The company maintains its full-year guidance, expecting high single-digit revenue growth on a currency-neutral basis for FY2025, with double-digit growth for the Adidas brand [4] Market Trends - The domestic market indices showed positive performance, with the Shanghai Composite Index closing at 3,617.60, up 0.96% [3] - The textile and apparel sector experienced a decline of 2.14% this week, underperforming the broader market [5] - Retail sales of sports and entertainment products grew significantly, with a 22.2% year-on-year increase in the first half of 2025 [5] Industry Dynamics - The Chinese gold consumption in the first half of 2025 was 505.205 tons, a decrease of 3.54% year-on-year, with jewelry consumption dropping by 26% [5] - The pharmaceutical industry is seeing advancements in innovative drugs, particularly in obesity treatments with GLP-1 and Amylin therapies showing promising results in clinical trials [8][11] - In the biopharmaceutical sector, ADC drugs for lung cancer are demonstrating significant efficacy, with several products showing improved outcomes in clinical trials [10][12]

Core Viewpoint - The stock price of Fuhong Hanlin (2696.HK) surged over 11% to reach a new high of 75 HKD, with a market capitalization exceeding 40 billion HKD, reflecting a reassessment of its long-term growth value in the innovative drug sector [1] Group 1: Stock Performance - The company's stock has been rising for multiple trading days since last week, driven by a strong performance in the innovative drug sector [1] - The market capitalization surpassing 40 billion HKD indicates recognition of the company's global strategy and continuous innovation capabilities [1] Group 2: Recent Developments - The company announced several innovative drug research results selected for the World Lung Cancer Conference (WCLC), including PD-L1 ADC and the combination therapy with Surulitinib [1] - The self-developed biosimilar HLX14 received a positive opinion from the European Medicines Agency (CHMP), marking a significant step towards European market entry [1] - Surulitinib's lung cancer indication has been approved in the UK and India, with commercial shipments initiated in India, the world's most populous country [1] Group 3: Product Pipeline - The company has multiple products approved for sale globally, with ongoing clinical and registration efforts in overseas markets [1]

Group 1 - The Hong Kong biotechnology stocks collectively rose, with notable increases in several companies' stock prices [1][2] - Beihai Kangcheng-B saw a rise of nearly 19%, while other companies like Gilead Sciences-B and Ascentage Pharma-B also experienced significant gains of over 15% and 9% respectively [1][2] - The overall trend indicates a positive sentiment in the biotechnology sector, with multiple companies achieving gains of over 5% [1][2] Group 2 - Specific stock performance includes: Beihai Kangcheng-B at 18.99% increase, Gilead Sciences-B at 15.30%, and Ascentage Pharma-B at 9.48% [2] - The market capitalization of these companies varies significantly, with Gilead Sciences-B at approximately 11.477 billion and Ascentage Pharma-B at about 29.86 billion [2] - Other notable performers include Jiahua Bio-B and Beikang Medical-B, both showing increases of over 7% [1][2]